Literature DB >> 25806331

Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?

Michail Charakidis1, Michael Boyer1.   

Abstract

Entities:  

Year:  2014        PMID： 25806331      PMCID： PMC4367679          DOI： 10.3978/j.issn.2218-6751.2014.09.03

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  3 in total

1.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

2.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

3.  Targeting MET Amplification as a New Oncogenic Driver.

Authors:  Hisato Kawakami; Isamu Okamoto; Wataru Okamoto; Junko Tanizaki; Kazuhiko Nakagawa; Kazuto Nishio
Journal:  Cancers (Basel)       Date:  2014-07-22       Impact factor: 6.639
  3 in total
  11 in total

1.  Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Authors:  Fernando C Santini; Siddharth Kunte; Alexander Drilon
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Authors:  Ahmad A Tarhini; Imran Rafique; Theofanis Floros; Phu Tran; William E Gooding; Liza C Villaruz; Timothy F Burns; David M Friedland; Daniel P Petro; Mariya Farooqui; Jose Gomez-Garcia; Autumn Gaither-Davis; Sanja Dacic; Athanassios Argiris; Mark A Socinski; Laura P Stabile; Jill M Siegfried
Journal:  Cancer       Date:  2017-05-04       Impact factor: 6.860

3.  Ten years of anti-vascular endothelial growth factor therapy.

Authors:  Napoleone Ferrara; Anthony P Adamis
Journal:  Nat Rev Drug Discov       Date:  2016-01-18       Impact factor: 84.694

4.  A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Authors:  Trever G Bivona; Robert C Doebele
Journal:  Nat Med       Date:  2016-05-05       Impact factor: 53.440

5.  Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.

Authors:  Katharine D Grugan; Keri Dorn; Stephen W Jarantow; Barbara S Bushey; Jose R Pardinas; Sylvie Laquerre; Sheri L Moores; Mark L Chiu
Journal:  MAbs       Date:  2016-10-27       Impact factor: 5.857

Review 6.  Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

Authors:  Ki-Hyun Kim; Hyori Kim
Journal:  Exp Mol Med       Date:  2017-03-24       Impact factor: 8.718

7.  TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.

Authors:  Raffaella Castoldi; Jürgen Schanzer; Christian Panke; Ute Jucknischke; Natalie J Neubert; Rebecca Croasdale; Werner Scheuer; Johannes Auer; Christian Klein; Gerhard Niederfellner; Sebastian Kobold; Claudio Sustmann
Journal:  Protein Eng Des Sel       Date:  2016-08-29       Impact factor: 1.650

Review 8.  A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.

Authors:  Katherine Emilie Rhoades Smith; Mehmet Asim Bilen
Journal:  Kidney Cancer       Date:  2019-11-01

9.  A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.

Authors:  Ryo Fujita; Vincent Blot; Eley Wong; Christine Stewart; Vincent Lieuw; Robyn Richardson; Ammar Banah; Jose Villicana; Anjuli Timmer; Julia Coronella; Roland Newman; Marco Gymnopoulos
Journal:  Cancer Biol Ther       Date:  2020-03-19       Impact factor: 4.742

10.  Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers.

Authors:  Yingnan Si; Kai Chen; Hanh Giai Ngo; Jia Shiung Guan; Angela Totoro; Zhuoxin Zhou; Seulhee Kim; Taehyun Kim; Lufang Zhou; Xiaoguang Liu
Journal:  Pharmaceutics       Date:  2022-01-07       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.